HC Wainwright reissued their buy rating on shares of I-Mab (NASDAQ:IMAB - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $8.00 target price on the stock.
I-Mab Stock Performance
Shares of IMAB traded down $0.03 on Friday, reaching $1.04. The stock had a trading volume of 260,753 shares, compared to its average volume of 349,142. I-Mab has a twelve month low of $0.99 and a twelve month high of $2.54. The firm has a 50-day moving average of $1.19 and a 200 day moving average of $1.42.
I-Mab (NASDAQ:IMAB - Get Free Report) last issued its earnings results on Wednesday, August 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.44. As a group, equities analysts anticipate that I-Mab will post -0.38 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Caligan Partners LP lifted its stake in shares of I-Mab by 3.7% in the 3rd quarter. Caligan Partners LP now owns 3,499,330 shares of the company's stock valued at $4,339,000 after purchasing an additional 124,539 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in I-Mab in the third quarter worth $179,000. Finally, Bank of Montreal Can acquired a new stake in I-Mab in the 2nd quarter valued at $453,000. Institutional investors and hedge funds own 38.38% of the company's stock.
I-Mab Company Profile
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
See Also
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
